Benefits and risks of cannabinoids

Tom P. Freeman, Wayne Hall

Research output: Contribution to journalEditorial

1 Citation (SciVal)
88 Downloads (Pure)


Cannabis is used by an estimated 219 million adults globally (4.3% of the population) with a particularly high prevalence in North America (17.4% of the population).1 The 1961 UN Single Convention on Narcotic Drugs included cannabis with opioids and cocaine as a controlled substance whose use was prohibited, but policies have changed considerably in recent decades. Medical use of cannabis is now permitted in large parts of North and South America, Europe, and Oceania; although, patient access varies considerably across jurisdictions. The use of cannabis for non-medical purposes is also now permitted in Canada, 22 US states, and Uruguay, and several other countries are considering allowing adult use in some form (eg, Germany, Luxembourg, Malta, the Netherlands, and Switzerland). In this rapidly changing policy climate, high quality evidence on benefits and risks are needed to inform policy and clinical practice.
Original languageEnglish
Article numberp2113
Number of pages2
JournalBMJ (Clinical research ed.)
Publication statusPublished - 18 Sept 2023

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Benefits and risks of cannabinoids'. Together they form a unique fingerprint.

Cite this